Table 3 Surgery plus adjuvant endocrine therapy vs primary endocrine therapy results
Trial | Median Follow up | Surgery n/N | Primary endocrine therapy n/N | HR (95% CI) |
|---|---|---|---|---|
Surgery plus endocrine therapy vs primary endocrine therapy | ||||
Mortality (‘OS’) | ||||
CRC | 13 years | 159/225 | 187/230 | 0.78 (0.63–0.96) |
GRETA | 7 years | 130/239 | 144/235 | 0.98 (0.77–1.25) |
Nottingham 2 | 5 years | 8/53 | 14/94 | 0.80 (0.73–2.32) |
Mortality or progression (‘PFS’) | ||||
CRC | 13 Years | NR | NR | NR |
GRETA | 7 years | 140/239 | 188/235 | 0.65 (0.53–0.81) |
Nottingham 2 | 5 years | NR | NR | NR |
Local recurrence or local progression as first event | ||||
CRC | 13 years | 36/225 | 115/230 | 0.25 (0.19–0.32) |
GRETA | 7 years | 27/239 | 95/235 | 0.38 (0.25–0.57) |
Nottingham 2 | 3 years | 2/53 | 30/94 | Not estimable |
Distant metastases as first or simultaneous event | ||||
CRC | 13 years | 20/225 | 14/235 | Not estimable |
GRETA | 7 years | 0/225 | 10/235 | Not estimable |
Nottingham 2 | 3 years | NR | NR | Not estimable |
